About AIM Therapeutics
AIM Therapeutics is a pharmaceutical company focused on developing medical treatments for inflammatory and immune disorders including asthma, spinal cord injury, and restenosis.
Missing: AIM Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: AIM Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
AIM Therapeutics Frequently Asked Questions (FAQ)
When was AIM Therapeutics founded?
AIM Therapeutics was founded in 2005.
Where is AIM Therapeutics's headquarters?
AIM Therapeutics's headquarters is located at MaRS Centre, Heritage Building, Toronto.
Who are AIM Therapeutics's competitors?
Competitors of AIM Therapeutics include Neos Therapeutics, Acorda Therapeutics, Embera NeuroTherapeutics, Akebia Therapeutics, Synapsin Pharmaceuticals and 8 more.
Compare AIM Therapeutics to Competitors
Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.
Q Therapeutics, Inc. is developing glial cell-based therapeutic products for central nervous system disorders in which a disease or injury inhibits normal myelin growth and enzyme performance.
Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.
Ikano Therapeutics is a specialty pharmaceutical company focused on developing nasally delivered pharmaceutical products with a particular focus on drugs treating pain and disorders related to the central nervous system.
Tarsa Therapeutics develops therapies for the treatment and prevention of osteoporosis and related bone diseases. The company is developing OSTORA, an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis. OSTORA is expected to be the first approved oral calcitonin, a natural hormone with a long history of safety and efficacy as an osteoporosis therapy. Availability of an oral calcitonin for osteoporosis is expected to generate wider use as doctors and patients are seeking new options that are safe and effective.
Intranasal Therapeutics, founded in 1998 by Edwin Cohen, founder and former Chairman and CEO of Barr Laboratories, Intranasal Therapeutics, Inc. (ITI) is a specialty pharmaceutical company focused on developing nasally delivered pharmaceutical products, with a particular focus on drugs treating pain and disorders related to the central nervous system.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.